Risk factor
Considerable default risk
Profitability factor
Greatly overvalued vs peers
About
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of 4552.T is 663 and suggests 28.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc